Veterans Try Controversial PTSD Treatment

July 2, 2026

Soldier in camouflage sits with head in hands during counseling session

For the first time, the Department of Veterans Affairs is testing MDMA-assisted therapy in a federally run clinical trial to determine whether it can help veterans with severe PTSD and alcohol use disorder after conventional treatments have fallen short.

Story Snapshot

The Department of Veterans Affairs is running a randomized MDMA trial for veterans with both PTSD and alcohol use disorder.
About 80 veterans will get either MDMA-assisted therapy or the same therapy with an active placebo at VA sites in Rhode Island and Connecticut.
The study uses pharmaceutical-grade MDMA under strict safety rules worked out with the Food and Drug Administration (FDA).
Earlier studies showed promising results, but FDA reviewers raised concerns about trial design and declined to approve MDMA therapy, making this VA study especially significant.

What This New VA MDMA Trial Is Doing

The Department of Veterans Affairs has launched a clinical trial to test MDMA-assisted therapy for veterans who have both post-traumatic stress disorder and alcohol use disorder. Unlike earlier research led primarily by universities and nonprofit organizations, this study is being conducted directly within the VA healthcare system. The trial, formally titled “A Randomized Controlled Trial of MDMA-Assisted Therapy for PTSD and Alcohol Use Disorder in U.S. Veterans,” is registered on ClinicalTrials.gov under the identifier NCT07118839, giving it full public and scientific visibility.

The study plans to enroll about 80 veterans and randomly assign them to one of two groups. One group will receive MDMA during several therapy sessions, while the other will get the same counseling but with an “active placebo” designed to mimic some effects without delivering a full MDMA dose. Both groups go through a structured, multi-month program that includes preparation, medicine sessions, and integration therapy to help process what comes up, aiming to see if adding MDMA improves symptoms beyond talk therapy alone.

Where, How, and Under What Safety Rules

The trial is being run at the VA Providence Healthcare System in Rhode Island and the VA Connecticut Healthcare System in West Haven, Connecticut. Veterans will be treated only in clinical settings and will receive pharmaceutical-grade MDMA made under strict quality controls. The VA says dosing, monitoring plans, and emergency procedures were developed together with the Food and Drug Administration, and all sessions will be supervised by trained therapist pairs who follow detailed protocols from earlier MDMA studies.

Each veteran in the study will take part in several non-drug therapy meetings before and after the medicine sessions. During the MDMA or placebo visits, they will be watched closely for changes in blood pressure, heart rate, mood, and behavior, with medical staff ready to step in if needed. The main outcomes the team will track include changes in PTSD symptom scores, daily functioning, and drinking patterns over time, using standard tools such as the Clinician Administered PTSD Scale and detailed alcohol use logs.

Why MDMA, And Why Now?

Researchers believe MDMA may temporarily reduce fear responses while increasing emotional openness, potentially allowing patients to engage more effectively with trauma-focused psychotherapy. Earlier Phase 3 trials run outside the VA found that MDMA-assisted therapy helped many civilians with chronic PTSD, with about two-thirds no longer meeting PTSD criteria by the end of treatment. These results, plus rising veteran suicide and addiction concerns, pushed the VA and Congress to explore psychedelic-assisted treatments after decades of relying mainly on medications and standard counseling.

What changed: in May 2026 the VA launched its own clinical trial of MDMA-assisted therapy for PTSD and alcohol use disorder — about 80 veterans, run through VA sites in Providence, RI and West Haven, CT.

— Psychedelic Vets (@PsychedelicVets) June 29, 2026

At the same time, there are reasons for caution that matter to both conservatives and liberals watching this trend. A Food and Drug Administration advisory panel recommended against approving MDMA for PTSD in 2024 because of worries about study design, masking, and bias, even with strong symptom drops. Although MDMA remains a Schedule I controlled substance under federal law, researchers can study it under tightly regulated clinical protocols approved by federal authorities.

Who Can Join, And What Veterans Should Weigh

The VA trial focuses on veterans whose PTSD and alcohol use disorder have not responded well to first-line evidence-based treatments such as standard trauma-focused therapy or certain medications. To qualify, veterans must have tried and stopped at least one such treatment, which means the study is aimed at treatment-resistant cases rather than everyone with PTSD. People with recent serious suicide risk or very high suicidal thinking scores are excluded, so the findings may not apply to the most fragile veterans.

For interested veterans, enrollment began in May and continues as the VA screens candidates through the Providence and West Haven centers. The trial is designed for veterans who have not improved with standard evidence-based treatments, making it a potential option for some of the most difficult-to-treat cases. Whether the trial ultimately succeeds or not, its findings could play an important role in shaping how the VA approaches PTSD treatment for veterans in the years ahead.

How This Fits Into The Bigger Fight Over Veteran Care

This MDMA trial is part of a larger shift where the VA is backing at least nineteen psychedelic studies and Congress has put new money into trials of MDMA, psilocybin, and other compounds. The move follows President Trump’s executive order on “Accelerating Medical Treatments for Serious Mental Illness,” which calls for faster testing and approval paths for new drugs, including psychedelics. Supporters argue the VA should investigate every promising option for veterans with treatment-resistant PTSD, while critics emphasize the need for long-term safety data before broader adoption.